Skip to main content
Fig. 1 | Journal of Experimental & Clinical Cancer Research

Fig. 1

From: STOML2 interacts with PHB through activating MAPK signaling pathway to promote colorectal Cancer proliferation

Fig. 1

STOML2 is highly expressed and predicts poor prognosis in CRC patients. a Representative images of STOML2 staining in CRC, paired normal, cancer and metastatic lymph nodes tissues of internal cohort. Scale bar, 200 μm. b Representative images of STOML2 staining in CRC tumor-adjacent tissues of internal cohort; left: scale bar, 200 μm. right: magnified image of boxed area on the left, scale bar, 40 μm.; dotted line outlines invasive front. c Kaplan-Meier curves of CRC patients’ overall survival with high or low STOML2 expression level of internal cohort. ***P < 0.001, log-rank test. d-e Immunoblot of STOML2 and GAPDH in paired normal and tumor tissue of twelve CRC cases from internal cohort; (d) N, normal colon; T, tumor. (e) Relative intensity of STOML2 immunoblot assay, ***P < 0.001, t test. f-h External validation of STOML2 expression in different cancers from GEO database. (f) GSE24514 dataset, CRC, normal tissue vs. cancer (n = 15 vs. 34). (g) GSE20916 dataset, CRC, normal tissue vs. adenoma vs. cancer (n = 34 vs. 54 vs. 66). (h) GSE41258 dataset, CRC, normal colon polyp vs. cancer (n = 54 vs. 49 vs. 186), normal liver vs. liver metastasis (n = 13 vs. 47), normal lung vs. lung metastasis (n = 7 vs. 20). Data was presented as means ± SEM from five independent experiments. *** P < 0.001, t test

Back to article page